ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Ionic Liquids

i2O launches for ionic liquid–based drug delivery

by Michael McCoy
April 18, 2020 | APPEARED IN VOLUME 98, ISSUE 15

 

i2O Therapeutics has launched with $4 million in seed funding from Sanofi Ventures and the JDRF T1D Fund to develop ionic liquid–based drug delivery technology. Using ionic liquid technology from the lab of Harvard University bioengineer Samir Mitragotri, i2O hopes to create oral forms of drugs that now must be delivered via needle. Its first target is GLP-1analogs, which help balance glucose levels to treat diabetes.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment